Cover Image
市場調查報告書

直腸癌:開發中產品分析

Rectal Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229750
出版日期 內容資訊 英文 107 Pages
訂單完成後即時交付
價格
Back to Top
直腸癌:開發中產品分析 Rectal Cancer - Pipeline Review, H2 2016
出版日期: 2016年08月17日 內容資訊: 英文 107 Pages
簡介

直腸癌是結腸(連接大腸跟肛門的部分)下半部產生的腫瘤。直腸癌發病的風險要素包含了年齡和抽煙、結腸癌·直腸癌的家族病史、高脂肪食物或動物主體的飲食,息肉·大腸癌的家族病史等。此外主要會轉移到肝臟及肺臟等組織。一般症狀有排便習慣的變化、下痢、便秘、不完全排便感、血便、頻繁的漲氣、飽脹感、痙攣,原因不明的體重減輕,頻繁的倦怠感·噁心等。主要的治療方法有外科手術及放射線治療、化療,及以上的綜合療法。

本報告提供全球各國治療直腸癌所用的開發中產品開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

直腸癌概要

治療藥的開發

  • 直腸癌開發中產品:概要

各企業開發中的直腸癌治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

直腸癌治療藥:開發中的產品一覽(各企業)

直腸癌治療藥的開發企業

  • AbbVie Inc
  • Advaxis, Inc.
  • Cerulean Pharma, Inc.
  • Hanwha Chemical Corporation
  • Karyopharm Therapeutics, Inc.
  • Regeneron Pharmaceuticals Inc
  • Taiwan Liposome Company, Ltd.

直腸癌:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

直腸癌治療藥:開發暫停的產品

直腸癌相關產品的開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8371IDB

Summary

Global Markets Direct's, 'Rectal Cancer - Pipeline Review, H2 2016', provides an overview of the Rectal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Rectal Cancer
  • The report reviews pipeline therapeutics for Rectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Rectal Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Rectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Rectal Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Rectal Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rectal Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Rectal Cancer - Overview
  • Rectal Cancer - Therapeutics under Development by Companies
  • Rectal Cancer - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Rectal Cancer - Products under Development by Companies
  • Rectal Cancer - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Advaxis, Inc.
    • Cerulean Pharma, Inc.
    • Hanwha Chemical Corporation
    • Karyopharm Therapeutics, Inc.
    • Regeneron Pharmaceuticals Inc
    • Taiwan Liposome Company, Ltd.
  • Rectal Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • axalimogene filolisbac - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CRLX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ganetespib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HD-204 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nimotuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • selinexor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TLC-388 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • veliparib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ziv-aflibercept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Rectal Cancer - Dormant Projects
  • Rectal Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Apr 23, 2014: Abbvie To Present Data On Veliparib At The 2014 American Society Of Clinical Oncology Annual Meeting
      • Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Rectal Cancer, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Rectal Cancer - Pipeline by AbbVie Inc, H2 2016
  • Rectal Cancer - Pipeline by Advaxis, Inc., H2 2016
  • Rectal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2016
  • Rectal Cancer - Pipeline by Hanwha Chemical Corporation, H2 2016
  • Rectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Rectal Cancer - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Rectal Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Rectal Cancer - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Rectal Cancer, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top